On Nov 22, major Wall Street analysts update their ratings for $Sage Therapeutics (SAGE.US)$, with price targets ranging from $8 to $14.
TD Cowen analyst Ritu Baral maintains with a hold rating, and maintains the target price at $9.
Oppenheimer analyst Jay Olson maintains with a hold rating, and adjusts the target price from $17 to $8.
Truist Financial analyst Joon Lee maintains with a hold rating.
Scotiabank analyst George Farmer maintains with a buy rating, and maintains the target price at $14.
Furthermore, according to the comprehensive report, the opinions of $Sage Therapeutics (SAGE.US)$'s main analysts recently are as follows:
Following the announcement that the phase 2 DIMENSION trial evaluating dalzanemdor in cognitive impairment associated with Huntington's disease failed to achieve the primary endpoint, the value assigned to this pipeline has been adjusted by removing $75M. The company has emphasized other assets in the early-stage pipeline; however, it is noted that significant clinical validation will be required before additional value can be attributed to these assets.
Sage Therapeutics announced that dalzanemdor did not meet the primary endpoint of change from baseline on the Symbol Digit Modalities Test at day 84 in the Phase 2 Huntington's cognitive impairment study. No statistically significant or clinically meaningful differences were observed on secondary endpoints.
Here are the latest investment ratings and price targets for $Sage Therapeutics (SAGE.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.